CLASS II Drug recall · Reported 15 Feb 2023 · FDA Enforcement Report

Posaconazole Delayed-Release Tablets, 100 mg recalled by Biocon Pharma

Biocon Pharma is recalling Posaconazole Delayed-Release Tablets, 100 mg, distributed nationwide in the US. The recall was initiated on 31 Jan 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: BF21003163, BF21003246, BF21003161, Exp. Sep-2023; BF21004742, Exp. Dec-2023; BF22003359, Exp. Sep-2025
NDC70377-038
Quantity recalled3665 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0268-2023
FDA event ID
91577
Recalling firm
Biocon Pharma, ISELIN, NJ
Manufacturer
Biocon Phama Inc.
Classification
Class II
Status
Terminated
Recall initiated
31 Jan 2023
FDA classified
14 Feb 2023
Reported
15 Feb 2023
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Potency & Assay

Timeline

31 Jan 2023Recall initiated by company
14 Feb 2023Classified by FDA+14 days
15 Feb 2023Published in enforcement report+1 day

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specifications: High Out Of Specification degradation results.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Posaconazole Delayed-Release Tablets, 100 mg, 60-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ 08830-3009; Manufactured by: Biocon Pharma Limited, Bengaluru, India - 560 099, NDC 70377-038-11.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Failed Impurities/Degradation Specifications: High Out Of Specification degradation results.

Which lots are affected?

Lot #: BF21003163, BF21003246, BF21003161, Exp. Sep-2023; BF21004742, Exp. Dec-2023; BF22003359, Exp. Sep-2025

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Biocon Pharma

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIAtorvastatin Calcium Tablets USP 40 mg recalled by Biocon PharmaAtorvastatin CalciumBiocon PharmaPotency & AssayNationwide

Other Posaconazole recalls

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IINoxafil Powdermix (posaconazole) recalled by Merck Sharp & DohmeNoxafilMerck Sharp & DohmeParticulate MatterNationwide